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aBVF Predicts Knee OA Structural Progression
Predictor Range of
predictor
values
Proportion of
medial JSN
progression
OR for medial
JSN progression
Baseline aBVF (0.008 - 0.06) lowest quartile 12/121 (9.9%) Referent
(0.06 - 0.09) 11/117 (9.4%) 0.9 (0.4 - 2.2)
(0.09 - 0.13) 9/108 (8.3%) 0.8 (0.3 - 2.0)
(0.13 - 0.54) highest quartile 24/116 (20.7%) 2.4 (1.1 - 5.0)
p for trend ¼ 0.02
aBVF
change(per yr)
(-0.22 - -0.01) lowest quartile 7/112 (6.3%) Referent
(-0.01 - 0) 13/115 (11.3%) 2.0 (0.8 - 5.2)
(0 - 0.01) 12/114 (10.5%) 1.8 (0.7 - 4.9)
(0.01 - 0.18) highest quartile 24/116 (20.1%) 4.1 (1.7 - 10.0)
p for trend ¼ 0.002
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ARGS NEOEPITOPE, PRESUMABLY DERIVED FROM ADAMTS5 ACTIVITY,
IS ELEVATED IN SERUM AND URINE FROM OSTEOARTHRITIS PATIENTS
UNDERGOING KNEE REPLACEMENT
F.M. Germaschewski 1, L.R. Cooper 1, F. Liu 2, J. Larkin 2, S. Woodward 3,
A.-C. Bay-Jensen 4, M. Karsdall 4, C. Matheny 2. 1GlaxoSmithKline,
Stevenage, Herts, UNITED KINGDOM; 2GlaxoSmithKline, Philadelphia, PA;
3 Synarc, Paris, FRANCE; 4Nordic BioSci., Herlev, DENMARK
Purpose: Proteolytic degradation of aggrecan in articular cartilage is
a characteristic feature of osteoarthritis (OA). ADAMTS5-mediated
cleavage of aggrecan generates the 374ARGS neoepitope. The objective of
this study was to evaluate 374ARGS levels in variousmatrices from different
OA populations in contrast to human subjects and assess performance of
a sensitive target-speciﬁc immunoassay to facilitate the clinical develop-
ment of an ADAMTS5 inhibitor for the treatment of OA.
Methods:Matched sera and urine were collected from 20 healthy subjects
(13 women, 7 men) aged from 26 to 60 years (mean  SD: 43.28.4) and
from 20 subjects with knee OA (12women, 8 men aged from 49 to 77 years
(meanSD: 66.1 7.36). Matched serum, urine and synovial ﬂuid was
obtained from 19 subjects undergoing joint replacement for knee OA (15
women, 9 men) aged from 47 to 85 years (meanSD: 69.111.30). Diurnal
and inter-day variation (over 3 visits) was evaluated in the non-surgical OA
group. Serum and urine samples were collected on two visits for the
patients undergoing knee replacement with synovial ﬂuid taken only at
the time of surgery. Correlation to additional biomarkers including OSM,
COMP, PIIANP, CTX-II, CTX-1, OC, hsCRP, CPII, CIIM, AGNx-1 was assessed.
ARGS neoepitope was quantitated using a chemiluminescent Meso-Scale-
Discovery (MSD) immunoassaywhich had been optimised and validated in
serum, plasma, urine and synovial ﬂuid. In brief, a commercial anti-
aggrecan capture antibody was coupled with a sulfo TAG labelled GSK
antibody speciﬁc to the 374ARGS neoepitope (OA-1). 374ARGS standard was
generated by digestion of aggrecan with ADAMTS5 which was diluted in
appropriate matrices pre-depleted of 374ARGS. The lower limit of quanti-
ﬁcation was 1.37, 0.46, and 4.12 ng/mL in serum, urine, and synovial ﬂuid
respectively.
Results: The mean concentration of 374ARGS neoepitope in serum from
healthy subjects was 4.32.2ng/mL (range 0.9-8.9 ng/mL), 5.92.7ng/mL
(range 1.1-10.0) in non-surgical OA subjects, and 9.34.6ng/mL (range 2.0-
16.5) in the surgical OA patients. Synovial ﬂuid concentrations of 374ARGS
in the surgical OA patients were similar to serum levels in those patients
(meanSD: 8.285.29). 374ARGS levels were lower in urine than serum in
all subjects but showed a similar trend of elevation in the surgical OA
patients (meanSD 5.94.5 range 0.5-13.9) compared to 3.312.28
(meanSD) in non-surgical OA patients (range 0.5-8.7) and 2.73.3
(meanSD) in healthy subjects (range 0-10.8). Compared to healthy
subjects, both serum (p¼0.004) and urine levels (p¼0.008) of 374ARGS
were signiﬁcantly elevated in the surgical OA patients. No signiﬁcant
difference was seen between healthy and non-surgical OA subjects. No
signiﬁcant diurnal effect or inter-day variance was observed in urine or
serum. Serum levels of 374ARGS correlated positively with COMP and CTX-
II (p<0.05) but not with other markers (OSM, PIIANP, CTX-1, OC, hsCRP,
CPII, CIIM, AGNx-1).Conclusions: This study utilized a highly sensitive and robust assay to
provide an initial evaluation of 374ARGS neoepitope concentrations in
various matrices in OA patients and healthy volunteers. There was
a general trend for increasing 374ARGS neoepitope concentration in serum
going from healthy subjects to non-end stage knee OA patients to end
stage (knee replacement) knee OA. Additional studies are planned to
evaluate 374ARGS as a diagnostic tool to facilitate patient selection as well
as provide an early indication of the pharmacodynamic effects of an
ADAMTS5 inhibitor in clinical trials.
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GENES ASSOCIATED WITH OSTEOARTHRITIS IDENTIFIED BY
MICROARRAY-ANALYSIS OF WHOLE BLOOD SAMPLES LINK OA TO
APOPTOTIC PATHWAYS
Y.F. Ramos 1, S.D. Bos 1, N. Lakenberg 1, M. Kloppenburg 2,
P.E. Slagboom1,3, I. Meulenbelt 1. 1Dept. of Molecular Epidemiology, LUMC,
Leiden, NETHERLANDS; 2Depts. of Clinical Epidemiology and Rheumatology,
LUMC, Leiden, NETHERLANDS; 3Netherlands Genomics Initiative-sponsored
Netherlands Consortium for Hlth.y Aging (NGI-NCHA), Leiden, NETHERLANDS
Purpose: Recently, genome wide association (GWA) studies have been
performed and the ﬁrst consistent OA-susceptibility loci have emerged.
Nevertheless, additional insight about the molecular and cellular aspects
of osteoarthritis (OA) is necessary. Gene expression proﬁling of peripheral
blood cells may be a valuable tool for assessing signatures of differential
gene expression related to disease. In the current study, an extensive large
scale exploration of gene expressionwas performed in mononuclear blood
cells of distinct osteoarthritis (OA) cases of the GARP study and their age-
and disease-matched controls.
Methods: We used a subset of 108 samples from the GARP-study which
consists of Dutch sibling pairs with symptomatic and radiographic OA in
two or more joint sites of the hand, spine (cervical or lumbar), knee or hip.
As comparison we included 33 age-matched controls without any radio-
graphic or symptomatic OA in the indicated joints. RNA was isolated
speciﬁcally of mononuclear blood cells after Histopaque separation.
Microarray analysis was performed on Illumina Human HT-12_v3_Bead-
Chips after conﬁrming integrity of the RNA with lab-on-a-chip. Pathway
analysis was performed with the Database for Annotation, Visualization
and Integrated Discovery (DAVID) tool.
Results: Data obtained in this study showed high quality expression
proﬁles. After normalization, adjusting for sex and age and correcting for
multiple testing we found 567 probes representing 528 genes that showed
signiﬁcant differential expression between cases and controls. From these,
81 probes (79 genes) show a difference of 1.5 times or more (lowest P-
value ¼ 8.2*10-13). When the latter group of genes was used for gene
enrichment analysis in DAVID (GO-terms all Biological Pathways (BP_all)),
apoptosis was identiﬁed as a highly signiﬁcant pathway (P-value¼5.4*10-
3) due to differential expression of 13 genes herein. Notable in this pathway
was the differential expression of the well known apoptotic gene CASP3
which has also been linked to cartilage degradation in OA.
Conclusions: In this study, we have determined a distinctive gene
expression signature of blood from OA patients in comparison to age and
diseased matched controls. Interestingly, in this signature, genes involved
